Targeted radioantibodies:
Striking with exceptional power

Radioantibodies are a type of targeted therapy where an antibody is linked to a radioactive payload. This radioactive payload holds the power to kill cancer cells by destroying the cell from within.1

Each radioantibody is created by carefully selecting an antibody with a high affinity for a specific cancer target. This enables the radioantibody to home in and lock onto the surface of a cancer cell. Once attached, the radioantibody is drawn into the cells, delivering the radioactive payload adjacent to the nucleus. The resulting radiation field causes irreparable damage to the DNA, eventually killing the cancer cell. And because each radioantibody is carefully tailored to specifically target the cancer cells and the alpha radiation has a more focused range of emission, damage to healthy tissue is minimized.

Our technology improves upon the limitations of current radiotherapies, and we’re already making progress. Our research has determined that alpha-emitting radioantibodies offer improved precision and potency over other technologies, including those relying on beta-emitting isotopes such as lutetium-177 (Lu-177).

Radioantibody
Particle animation
Particle animation
Particle animation

For tumors, targeted
action
leads to deadly
reaction

An antibody linking to an alpha radionuclide payload.

Proprietary antibodies are linked to an alpha radionuclide payload (such as actinium-225 [Ac-225]), forming a highly potent therapy. The choice of radionuclide is based on factors including physical properties, desired radiation dose, and cancer type

An radioantibody binding to a target on the surface of cancer cells

Radioantibodies locate and bind to targets on the surface of tumor cells

Radioantibody being internalized into a cancer cell

The radioantibodies are internalized into cancer cells where they deliver their radioactive payload near the nucleus of the cell

Damage caused by the radioantibody in a cancer cell

This causes irreparable DNA damage that kills the cell

Cell on purple background Cell on purple background

Unleashing the
power of
radioantibodies

Convergent is developing radioantibodies that seek to improve
upon the safety and efficacy issues of current radiotherapies.

1. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005;46(Suppl 1):199S-204S.